Search Result

Results for "

CBP Bromodomain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Epigenetic Reader Domain (28) Histone Acetyltransferase (11) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (1) PROTACs (4)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Inflammation/Immunology (1) Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-136938

NEO2734 1 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-100697

TPOP146 3 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
TPOP146 is a selective *CBP/P300* benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.

HY-15826

SGC-CBP30 Maximum Cited Publications 13 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30 is a potent and highly selective **CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300*, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain* of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-164005

CBP/EP300 bromodomain receptor-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-157134

Y08262	Others	Cancer
Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC₅₀ value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .

HY-142743

Y08175	Epigenetic Reader Domain	Cancer
Y08175 is a potent **CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC₅₀*s of 37 and 178.15 nM against CBP* bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active **CBP bromodomain** inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .

HY-19541A

I-CBP112 hydrochloride	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of *CBP/P300* that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .

HY-19999

PF-CBP1	Epigenetic Reader Domain	Neurological Disease
PF-CBP1 is a highly selective inhibitor of the CREB binding protein bromodomain .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-19541

I-CBP112 3 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the **CBP/P300 family of bromodomains*. CBP/p300-IN-8 inhibits CBP* (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-19999A

PF-CBP1 hydrochloride 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease
PF-CBP1 hydrochloride is a highly selective inhibitor of the *CREB binding protein bromodomain* (CBP BRD)*. PF-CBP1 inhibits CREBBP* and EP300 bromodomains with?IC₅₀?of 125 nM and 363 nM respectively. PF-CBP1 hydrochloride reduces LPS-induced inflammatory cytokines expression (IL-1β,?IL-6?and?IFN-β) in primary macrophages. PF-CBP1 hydrochloride also downregulates?RGS4?expression cortical neurons and can be used for the research of neurological disorders, including epilepsy and parkinson's disease, et al .

HY-147869

DC-CPin7	Epigenetic Reader Domain	Cancer
DC-CPin7 is a potent inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 2.5 μM .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent *CBP/EP300* bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for *CBP, EP300* and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for *CBP* .

HY-141546

Pocenbrodib	Histone Acetyltransferase	Cancer
Pocenbrodib (compound II) is a *CBP/p300* family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research .

HY-120028

GNE-207	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of *CBP, with an IC₅₀* of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an EC₅₀ of 18 nM for MYC expression in MV-4-11 cells .

HY-110315

Ischemin sodium	Apoptosis MDM-2/p53 Epigenetic Reader Domain	Cardiovascular Disease
Ischemin sodium is a *CBP* bromodomain inhibitor that inhibits p53 interaction with *CBP* and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC₅₀ value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .

HY-101125A

L-Moses dihydrochloride 2 Publications Verification L-45 dihydrochloride	Epigenetic Reader Domain	Cancer
L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-101125

L-Moses 2 Publications Verification L-45	Epigenetic Reader Domain	Cancer
L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

HY-111784

Inobrodib 5+ Cited Publications CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .

HY-161960

EP300/CBP ligand 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-147868

DC-CPin711	Epigenetic Reader Domain Apoptosis	Cancer
DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis .

HY-154984

JET-209	Histone Acetyltransferase PROTACs	Cancer
JET-209 is a potent PROTAC *CBP/p300* degrader, with DC₅₀ values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 contains Lenalidomide (HY-A0003) (the cereblon ligand), a linker and GNE-207 (HY-120028) (bromodomain Inhibitor). JET-209 is used for cancer research .

HY-123758

XDM-CBP	Epigenetic Reader Domain	Cancer
XDM-CBP is a CBP/p300 inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .

HY-161958

dCE-2	PROTACs Histone Acetyltransferase	Cancer
dCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) ^{[1] ^.}

HY-149806

Bromodomain IN-2	Epigenetic Reader Domain	Cancer
BD-IN-1 is a pan bromodomain (BD) inhibitor with K_D values of 250, 420, 130, 430, 67, 240, 970 nM for BRD4(1), CBP, BRPF1B, BRD7, BRD9, BRDT(1), CECR2 respectively. BD-IN-1 shows antiproliferative activity .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-101125B

D-Moses D-45	Others	Cancer
D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

CBP Bromodomain

Inhibitors & Agonists